Cellectar Biosciences, Inc.
CLRB
$2.37
-$0.05-1.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.22% | 14.39% | -124.81% | 69.70% | -492.55% |
| Total Depreciation and Amortization | -36.15% | -295.38% | -27.84% | -23.76% | -15.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 319.15% | -59.64% | 103.39% | -90.86% | 100.71% |
| Change in Net Operating Assets | 177.37% | 114.56% | 1,061.48% | -107.93% | 111.80% |
| Cash from Operations | -17.49% | 48.36% | 60.20% | 53.36% | 63.83% |
| Capital Expenditure | -- | -- | 90.38% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 90.38% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,306.11% | -- | -- | -67.04% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,306.11% | -- | -- | -67.04% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 995.46% | 48.32% | 105.85% | -81.97% | 79.78% |